David Shaw’s Esperion Therapeutics ESPR Stock Holding History

David Shaw’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,500	Closed	-$63K	–	5639
2021 Q4	$63K	Hold	12,500	–	–	﹤0.01%	5157
2021 Q3	$151K	Buy	+12,500	New	+$182K	﹤0.01%	4633
2020 Q1	–	Sell	-30,000	Closed	-$1.79M	–	4017
2019 Q4	$1.79M	Sell	30,000 -50,000	-63%	-$2.25M	﹤0.01%	2567
2019 Q3	$2.93M	Buy	80,000 +50,000	+167%	+$1.98M	﹤0.01%	2067
2019 Q2	$1.4M	Buy	+30,000	New	+$1.41M	﹤0.01%	2478
2019 Q1	–	Sell	-12,900	Closed	-$593K	–	3686
2018 Q4	$593K	Hold	12,900	–	–	﹤0.01%	2999
2018 Q3	$572K	Hold	12,900	–	–	﹤0.01%	3031
2018 Q2	$506K	Buy	+12,900	New	+$652K	﹤0.01%	3110
2015 Q3	–	Sell	-6,500	Closed	-$531K	–	3763
2015 Q2	$531K	Hold	6,500	–	–	﹤0.01%	3131
2015 Q1	$602K	Buy	+6,500	New	+$419K	﹤0.01%	2944

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

David Shaw's ESPR Position: Q2 2026 in Review

David Shaw sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 6,540,785 shares — an estimated $17.9M sold.

David Shaw first reported a position in ESPR in Q1 2015 and held it in 24 quarters. The position peaked at $25.5M in Q4 2025. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

David Shaw reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
David Shaw sold 6,540,785 Esperion Therapeutics shares in Q2 2026, an estimated $17.9M.
David Shaw first reported a position in Esperion Therapeutics in Q1 2015 and held it in 24 quarters.
David Shaw's Esperion Therapeutics position peaked at $25.5M in Q4 2025.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.